GSK signs £3.8bn-equivalent of loans tied to RFRs
GlaxoSmithKlein, the UK pharmaceutical company, has refinanced dollar and sterling loans using risk-free rates, in one of the biggest transactions yet to avoid using Libor as the margin benchmark.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: